Clinton Group Inc. bought a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) during the first quarter, according to its most recent disclosure with the SEC. The firm bought 1,061 shares of the medical research company’s stock, valued at approximately $212,000.

A number of other hedge funds and other institutional investors have also modified their holdings of BIO. Seven Eight Capital LP acquired a new position in shares of Bio-Rad Laboratories during the fourth quarter valued at approximately $273,000. Tudor Investment Corp Et Al increased its position in shares of Bio-Rad Laboratories by 1,218.0% in the fourth quarter. Tudor Investment Corp Et Al now owns 59,100 shares of the medical research company’s stock valued at $10,773,000 after buying an additional 54,616 shares during the last quarter. Soros Fund Management LLC acquired a new position in shares of Bio-Rad Laboratories during the fourth quarter valued at approximately $401,000. Two Sigma Investments LP increased its position in shares of Bio-Rad Laboratories by 0.9% in the fourth quarter. Two Sigma Investments LP now owns 9,781 shares of the medical research company’s stock valued at $1,783,000 after buying an additional 87 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its position in shares of Bio-Rad Laboratories by 6.0% in the fourth quarter. Envestnet Asset Management Inc. now owns 5,315 shares of the medical research company’s stock valued at $970,000 after buying an additional 299 shares during the last quarter. 64.08% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Bio-Rad Laboratories, Inc. (NYSE BIO) opened at 220.61 on Friday. The stock has a 50 day moving average price of $222.09 and a 200 day moving average price of $199.75. The firm has a market cap of $6.53 billion, a P/E ratio of 234.19 and a beta of 0.88. Bio-Rad Laboratories, Inc. has a 1-year low of $135.94 and a 1-year high of $230.40.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, May 4th. The medical research company reported $0.41 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.14. The company had revenue of $500.05 million for the quarter, compared to analysts’ expectations of $477.76 million. Bio-Rad Laboratories had a return on equity of 3.23% and a net margin of 1.35%. Bio-Rad Laboratories’s revenue for the quarter was up 6.1% compared to the same quarter last year. During the same period last year, the firm posted $0.42 EPS. On average, analysts anticipate that Bio-Rad Laboratories, Inc. will post $2.85 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Clinton Group Inc. Invests $212,000 in Bio-Rad Laboratories, Inc. (BIO)” was first posted by Financial Market News and is the sole property of of Financial Market News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.financial-market-news.com/2017/06/17/clinton-group-inc-invests-212000-in-bio-rad-laboratories-inc-bio.html.

Several research analysts have recently issued reports on BIO shares. BidaskClub downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday. Zacks Investment Research raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating and set a $244.00 price objective for the company in a research note on Monday, May 1st. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $250.00 price objective on shares of Bio-Rad Laboratories in a research note on Thursday, April 27th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $217.25.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.